Patents on Pharmaceutical Products in Fair International Economic Relations
Abstract Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essen...
Gespeichert in:
Veröffentlicht in: | Perspectives on global development and technology 2019-05, Vol.18 (3), p.249-268 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 268 |
---|---|
container_issue | 3 |
container_start_page | 249 |
container_title | Perspectives on global development and technology |
container_volume | 18 |
creator | Mah, Jai S |
description | Abstract
Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations. |
doi_str_mv | 10.1163/15691497-12341521 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2269020098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2269020098</sourcerecordid><originalsourceid>FETCH-LOGICAL-b265t-da9c1e91c4f75399f6b949d0bf4b80fc6be658ecc35bf0e1dd8ecc98588798953</originalsourceid><addsrcrecordid>eNp1UMFOAyEQJUYTa_UDvG3ieS2zu1A4mqbVxiY2Rs8EWIg0W6jAHvx7d62NJ08z8968l5mH0C3gewBaz4BQDg2fl1DVDZAKztBkxMoRPD_1BONLdJXSDuMK1xgm6Hkrs_E5FcEX2w8Z91KbPjstu2IbQ9vrgXK-WEkXi7XPJnqZXfADvdTBh73TxavpfrB0jS6s7JK5-a1T9L5avi2eys3L43rxsClVRUkuW8k1GA66sXNSc26p4g1vsbKNYthqqgwlzGhdE2WxgbYdB84IY3POOKmn6O7oe4jhszcpi13oh8O6JKqK8uE1zNmwBcctHUNK0VhxiG4v45cALMbMxCkzccps0MyOGhVd1_3Z_q_4Bi4BbLg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2269020098</pqid></control><display><type>article</type><title>Patents on Pharmaceutical Products in Fair International Economic Relations</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Worldwide Political Science Abstracts</source><source>Sociological Abstracts</source><source>EBSCOhost Business Source Complete</source><creator>Mah, Jai S</creator><creatorcontrib>Mah, Jai S</creatorcontrib><description>Abstract
Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations.</description><identifier>ISSN: 1569-1500</identifier><identifier>EISSN: 1569-1497</identifier><identifier>DOI: 10.1163/15691497-12341521</identifier><language>eng</language><publisher>Leiden | Boston: Brill</publisher><subject>Developing countries ; Drugs ; Fairness ; GATT ; Intellectual property ; International economic relations ; International economics ; International trade ; LDCs ; Negotiation ; Pharmaceuticals ; Property rights</subject><ispartof>Perspectives on global development and technology, 2019-05, Vol.18 (3), p.249-268</ispartof><rights>Copyright 2019 by Koninklijke Brill NV, Leiden, The Netherlands</rights><rights>Copyright Brill Academic Publishers, Inc. May 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902,30976,33751</link.rule.ids></links><search><creatorcontrib>Mah, Jai S</creatorcontrib><title>Patents on Pharmaceutical Products in Fair International Economic Relations</title><title>Perspectives on global development and technology</title><description>Abstract
Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations.</description><subject>Developing countries</subject><subject>Drugs</subject><subject>Fairness</subject><subject>GATT</subject><subject>Intellectual property</subject><subject>International economic relations</subject><subject>International economics</subject><subject>International trade</subject><subject>LDCs</subject><subject>Negotiation</subject><subject>Pharmaceuticals</subject><subject>Property rights</subject><issn>1569-1500</issn><issn>1569-1497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>7UB</sourceid><sourceid>BHHNA</sourceid><recordid>eNp1UMFOAyEQJUYTa_UDvG3ieS2zu1A4mqbVxiY2Rs8EWIg0W6jAHvx7d62NJ08z8968l5mH0C3gewBaz4BQDg2fl1DVDZAKztBkxMoRPD_1BONLdJXSDuMK1xgm6Hkrs_E5FcEX2w8Z91KbPjstu2IbQ9vrgXK-WEkXi7XPJnqZXfADvdTBh73TxavpfrB0jS6s7JK5-a1T9L5avi2eys3L43rxsClVRUkuW8k1GA66sXNSc26p4g1vsbKNYthqqgwlzGhdE2WxgbYdB84IY3POOKmn6O7oe4jhszcpi13oh8O6JKqK8uE1zNmwBcctHUNK0VhxiG4v45cALMbMxCkzccps0MyOGhVd1_3Z_q_4Bi4BbLg</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Mah, Jai S</creator><general>Brill</general><general>Brill Academic Publishers, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7U4</scope><scope>7UB</scope><scope>8BJ</scope><scope>BHHNA</scope><scope>DWI</scope><scope>FQK</scope><scope>JBE</scope><scope>WZK</scope></search><sort><creationdate>20190501</creationdate><title>Patents on Pharmaceutical Products in Fair International Economic Relations</title><author>Mah, Jai S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b265t-da9c1e91c4f75399f6b949d0bf4b80fc6be658ecc35bf0e1dd8ecc98588798953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Developing countries</topic><topic>Drugs</topic><topic>Fairness</topic><topic>GATT</topic><topic>Intellectual property</topic><topic>International economic relations</topic><topic>International economics</topic><topic>International trade</topic><topic>LDCs</topic><topic>Negotiation</topic><topic>Pharmaceuticals</topic><topic>Property rights</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mah, Jai S</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Sociological Abstracts (pre-2017)</collection><collection>Worldwide Political Science Abstracts</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>Sociological Abstracts</collection><collection>Sociological Abstracts</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>Sociological Abstracts (Ovid)</collection><jtitle>Perspectives on global development and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mah, Jai S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patents on Pharmaceutical Products in Fair International Economic Relations</atitle><jtitle>Perspectives on global development and technology</jtitle><date>2019-05-01</date><risdate>2019</risdate><volume>18</volume><issue>3</issue><spage>249</spage><epage>268</epage><pages>249-268</pages><issn>1569-1500</issn><eissn>1569-1497</eissn><abstract>Abstract
Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations.</abstract><cop>Leiden | Boston</cop><pub>Brill</pub><doi>10.1163/15691497-12341521</doi><tpages>20</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1569-1500 |
ispartof | Perspectives on global development and technology, 2019-05, Vol.18 (3), p.249-268 |
issn | 1569-1500 1569-1497 |
language | eng |
recordid | cdi_proquest_journals_2269020098 |
source | Applied Social Sciences Index & Abstracts (ASSIA); Worldwide Political Science Abstracts; Sociological Abstracts; EBSCOhost Business Source Complete |
subjects | Developing countries Drugs Fairness GATT Intellectual property International economic relations International economics International trade LDCs Negotiation Pharmaceuticals Property rights |
title | Patents on Pharmaceutical Products in Fair International Economic Relations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T21%3A34%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patents%20on%20Pharmaceutical%20Products%20in%20Fair%20International%20Economic%20Relations&rft.jtitle=Perspectives%20on%20global%20development%20and%20technology&rft.au=Mah,%20Jai%20S&rft.date=2019-05-01&rft.volume=18&rft.issue=3&rft.spage=249&rft.epage=268&rft.pages=249-268&rft.issn=1569-1500&rft.eissn=1569-1497&rft_id=info:doi/10.1163/15691497-12341521&rft_dat=%3Cproquest_cross%3E2269020098%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2269020098&rft_id=info:pmid/&rfr_iscdi=true |